Глухова Е.А., Мухортых В.А., Тамразова О.Б., Таганов А.В., Ревякина В.А. Предикторы тяжелого течения атопического дерматита. Вопросы питания. 2022;91(1):76–85. https://doi.org/10.33029/0042-8833-2022-91-1-76-85..
DOI: 10.33029/0042-8833-2022-91-1-76-85
Siegfried E.C., Jaworski J.C., Kaiser J.D., Hebert A.A. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;(16):75. https://doi.org/10.1186/s12887-016-0607-9..
DOI: 10.1186/s12887-016-0607-9
Mancini A.J., Kaulback K., Chamlin S.L. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1–6. https://doi.org/10.1111/j.1525-1470.2007.00572.x..
DOI: 10.1111/j.1525-1470.2007.00572.x
Kim J.P., Chao L.X., Simpson E.L., Silverberg J.I. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681–687. https://doi.org/10.1016/j.jaad.2016.05.028..
DOI: 10.1016/j.jaad.2016.05.028
Boguniewicz M., Fonacier L., Guttman-Yassky E., Ong P.Y., Silverberg J., Farrar J.R. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. https://doi.org/10.1016/j.anai.2017.10.039..
DOI: 10.1016/j.anai.2017.10.039
Sayaseng K.Y., Vernon P. Pathophysiology and management of mild to moderate pediatric atopic dermatitis. J Pediatr Health Care. 2018;32(2):S2–S12. https://doi.org/10.1016/j.pedhc.2017.10.002..
DOI: 10.1016/j.pedhc.2017.10.002
Pustišek N., Živković M.V., Šitum M. Quality of life in fami lies with children with atopic dermatitis. Pediatr Dermatol. 2016;33(1):28–32. https://doi.org/10.1111/pde.12698..
DOI: 10.1111/pde.12698
Kuo I.H., Yoshida T., De Benedetto A., Beck L.A. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):266–278. https://doi.org/10.1016/j.jaci.2012.12.1563..
DOI: 10.1016/j.jaci.2012.12.1563
Boguniewicz M., Leung D.Y.M. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246. https://doi.org/10.1111/j.1600-065X.2011.01027.x..
DOI: 10.1111/j.1600-065X.2011.01027.x
Irvine A.D., Mclean W.H.I., Leung D.Y.M. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315–1327. https://doi.org/10.1056/NEJMra1011040..
DOI: 10.1056/NEJMra1011040
Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891..
DOI: 10.1111/jdv.14891
Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberg K. et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. https://doi.org/10.1016/j.jaad.2014.03.023..
DOI: 10.1016/j.jaad.2014.03.023
Kapur S., Watson W., Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(2):52. https://doi.org/10.1186/s13223-018-0281-6..
DOI: 10.1186/s13223-018-0281-6
Rathi S.K., D’Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57(4):251–259. https://doi.org/10.4103/0019-5154.97655..
DOI: 10.4103/0019-5154.97655
Hughes J., Rustin M. Corticosteroids. Clin Dermatol. 1997;15(5):715–721. https://doi.org/10.1016/s0738-081x(97)00020-5..
DOI: 10.1016/s0738-081x(97)00020-5
Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931–936. https://doi.org/10.1046/j.1365-2133.2000.03473.x.
DOI: 10.1046/j.1365-2133.2000.03473.x
Nghiem P., Pearson G., Langley R.G. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–241. https://doi.org/10.1067/mjd.2002.120942..
DOI: 10.1067/mjd.2002.120942
Reitamo S. Tacrolimus: a topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):445–448. https://doi.org/10.1067/mai.2001.113521..
DOI: 10.1067/mai.2001.113521
Santini M.P., Talora C., Seki T., Bolgan L., Dotto G.P. Cross talk among calcineurin, Sp1/Sp3, and NFAT in control of p21(WAF1/CIP1) expression in keratinocyte differentiation. Proc Natl Acad Sci USA. 2001;98(17):9575–9580. https://doi.org/10.1073/pnas.161299698..
DOI: 10.1073/pnas.161299698
Remitz A., Kyllönen H., Granlund H., Reitamo S. Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions. J Allergy Clin Immunol. 2001;107(1):196–197. https://doi.org/10.1067/mai.2001.112131..
DOI: 10.1067/mai.2001.112131
Boguniewicz M., Fiedler V.C., Raimer S., Lawrence I.D., Hanifin J.M. A randomized, vehicle controlled trial of tacrolimus ointment for the treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998;102(4):637–644. https://doi.org/10.1016/s0091-6749(98)70281-7..
DOI: 10.1016/s0091-6749(98)70281-7
Hanifin J.M., Ling M.R., Langley R., Breneman D., Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001;44(1):S28–38. https://doi.org/10.1067/mjd.2001.109810..
DOI: 10.1067/mjd.2001.109810
Paller A., Eichenfield L.F., Leung D.Y.M., Steward D., Appell M. A 12-week study of tacrolimus oint ment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44(1):S47–57. https://doi.org/10.1067/mjd.2001.109813..
DOI: 10.1067/mjd.2001.109813
Soter N.A., Fleischer A.B., Webster G.F., Monroe E., Lawrence I. Tacrolimus ointment for the treat ment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1):S39–46. https://doi.org/10.1067/mjd.2001.109817..
DOI: 10.1067/mjd.2001.109817
Frankel H.C., Qureshi A.A. Comparative Effectiveness of Topical Calcineurin Inhibitors in Adult Patients with Atopic Dermatitis. Am J Clin Dermatol. 2012;13(2):113–123. https://doi.org/10.2165/11597780-000000000-00000..
DOI: 10.2165/11597780-000000000-00000
Reitamo S., Rissanen J., Remitz A., Granlund H., Erkko P., Elg P. et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111(3):396–398. https://doi.org/10.1046/j.1523-1747.1998.00323.x..
DOI: 10.1046/j.1523-1747.1998.00323.x
Undre N.A., Moloney F.J., Ahmadi S., Stevenson P., Murphy G.M. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis British J Dermatol. 2009;160(3):665–669. https://doi.org/10.1111/j.1365-2133.2008.08974.x..
DOI: 10.1111/j.1365-2133.2008.08974.x
Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberger K. et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. https://doi.org/10.1016/j.jaad.2014.03.023..
DOI: 10.1016/j.jaad.2014.03.023
Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. https://doi.org/10.1111/jdv.14891..
DOI: 10.1111/jdv.14891
Sidbury R., Davis D.M., Cohen D.E., Cordoro K.M., Berger T.G., Bergman J.N. et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. https://doi.org/10.1016/j.jaad.2014.03.030..
DOI: 10.1016/j.jaad.2014.03.030
Nakahara T., Koga T., Fukagawa S., Uchi H., Furue M. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis. J Dermatol. 2004;31(7):524–528. https://doi.org/10.1111/j.1346-8138.2004.tb00548.x..
DOI: 10.1111/j.1346-8138.2004.tb00548.x
Кубанова А.А., Кубанов А.А., Самцов А.В., Аравийская Е.Р. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс; 2016. 748 с. Режим доступа: https://www.cnikvi.ru/docs/2335_maket_30.pdf.https://www.cnikvi.ru/docs/2335_maket_30.pdf
Кубанова А.А., Кубанов А.А., Самцов А.В., Аравийская Е.Р. Федеральные клинические рекомендации. Дерматовенерология 2015: Болезни кожи. Инфекции, передаваемые половым путем. 5-е изд., перераб. и доп. М.: Деловой экспресс; 2016. 748 с. Режим доступа: https://www.cnikvi.ru/docs/2335_maket_30.pdf.https://www.cnikvi.ru/docs/2335_maket_30.pdf
Sugarman J.H., Fleischer A.B., Feldman S.R. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47(2):217–223. https://doi.org/10.1067/mjd.2002.120469..
DOI: 10.1067/mjd.2002.120469
Gupta A.K., Versteeg S.G. Topical treatment of facial sebor rheic dermatitis: a systematic review. Am J Clin Dermatol. 2017;18(2):193–213. https://doi.org/10.1007/s40257-016-0232-2..
DOI: 10.1007/s40257-016-0232-2
Kuhn A., Gensch K., Haust M., Schneider S.W., Bonsmann G., GaebeleinWissing N. et al. Efficacy of tacrolimus 0,1[%] ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65(1):54–64. https://doi.org/10.1016/j.jaad.2010.03.037..
DOI: 10.1016/j.jaad.2010.03.037
Saripalli Y.V., Gadzia J.E., Belsito D.V. Tacrolimus ointment 0.1[%] in the treatment of nickel-induced allergic contact derma titis. J Am Acad Dermatol. 2003;49(3):477–482. https://doi.org/10.1067/s0190-9622(03)01826-7..
DOI: 10.1067/s0190-9622(03)01826-7
Pacor M.L., Di Lorenzo G., Martinelli N., Mansueto P., Friso S., Pellitteri M.E. et al. Tacrolimus oint ment in nickel sulphate-induced steroid-resistant allergic con tact dermatitis. Allergy Asthma Proc. 2006;27(6):527–531. https://doi.org/10.2500/aap.2006.27.2915..
DOI: 10.2500/aap.2006.27.2915
Belsito D., Wilson D.C., Warshaw E., Fowler J., Ehrlich A., Anderson B. et al. A prospective ran domized clinical trial of 0.1[%] tacrolimus ointment in a model of chronic allergic contact dermatitis. J Am Acad Dermatol. 2006;55(1):40–46. https://doi.org/10.1016/j.jaad.2006.03.025..
DOI: 10.1016/j.jaad.2006.03.025
Katsarou A., Makris M., Papagiannaki K., Lagogianni E., Tagka A., Kalogeromitros D. Tacrolimus 0.1[%] vs mometasone furoate topical treatment in allergic contact hand eczema: a prospective randomized clinical study. Eur J Dermatol. 2012;22(2):192–196. https://doi.org/10.1684/ejd.2011.1615..
DOI: 10.1684/ejd.2011.1615
Alomar A., Puig L., Gallardo C.M., Valenzuela N. Topical tacro limus 0.1[%] ointment (Protopic®) reverses nickel contact der matitis elicited by allergen challenge to a similar degree to mometasone furoate 0.1[%] with greater suppression of late erythema. Contact Dermatitis. 2003;49(4):185–188. https://doi.org/10.1111/j.0105-1873.2003.0217.x..
DOI: 10.1111/j.0105-1873.2003.0217.x
Müller G.G., José N.K., de Castro R.S. Topical tacrolimus 0,03[%] as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study. Eye Contact Lens. 2014;40(2):79–83. https://doi.org/10.1097/ICL.0000000000000001..
DOI: 10.1097/ICL.0000000000000001
Матушевская Е.В., Коцарева О.Д., Матушевская Ю.И., Свирщевская Е.В. Поддерживающая терапия при атопическом дерматите у взрослых и детей. Клиническая дерматология и венерология. 2017;16(4):14–20. https://doi.org/10.17116/klinderma201716414-20..
DOI: 10.17116/klinderma201716414-20
Cavalié M., Ezzedine K., Fontas E., Montaudié H., Castela E., Bahadoran P. et al. Maintenance therapy of adult vitiligo with 0,1[%] tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135(4):970–974. https://doi.org/10.1038/jid.2014.527..
DOI: 10.1038/jid.2014.527
Luger T., Boguniewicz M., Carr W., Cork M., Deleuran M., Eichenfield L. et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306–315. https://doi.org/10.1111/pai.12331..
DOI: 10.1111/pai.12331